On October 15, Eli Lilly and Company announced a definitive agreement to acquire Disarm Therapeutics, a privately-held biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration.
Disarm has discovered novel, potent SARM1 inhibitors and is advancing them in preclinical development, with the goal of delivering breakthrough treatments to patients with peripheral neuropathy and other neurological diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis. Lilly will seek to advance Disarm’s SARM1 inhibitors.
Under the terms of the agreement, Lilly will acquire Disarm for an upfront payment of $135 million, plus up to an additional $1.225 billion in potential milestone payments.
The WilmerHale team advising Disarm is led by Stuart Falber and includes Joseph Conahan, Steven Barrett, Ciara Baker, Scott Kilgore, William Caporizzo, Mark Nylen, Michael Lopes and Jenna Weissman.